Pulse

Viral tales told by signature mutations

Amit Chopra | | Updated on: Dec 26, 2021
image caption

Why we must keep track of how highly transmissible lineages evolve over time

 

All viruses mutate to survive and thrive in their environment. SARS-CoV-2 is no exception. And the highly mutated Omicron is the most recent ‘variant of concern’, designated by the World Health Organization (WHO).

Preliminary evidence suggests Omicron is more easily transmitted than its predecessors. As scientists learn more about the virus, new information is emerging rapidly about transmission, virulence, effectiveness of existing vaccines, and the impact of mutations on available molecular diagnostic tests.

Robust testing can help detect asymptomatic cases, which result in the inadvertent spread of disease. Currently, all reported cases of Omicron are mild or asymptomatic — stressing the need for more testing. Besides, the variant has been found to include the same mutation of S gene, first identified in the Alpha variant. This mutation causes a dropout of the S-gene target in results. Diagnostics tests that have a multi-target design can be used as an indicator for Omicron, prior to sequencing.

Genomic surveillance will be crucial for identifying new mutations and monitoring their spread. The ability to distinguish between variants may provide insights into SARS-CoV-2’s evolution.

The resurgence of new variants reminds us that it is critical to continually characterise virus strains and monitor the spread at the population level. This will help assess the effectiveness of containment strategies.

Detecting the signature mutations in these highly transmissible lineages is important, not only for confirming the lineage but also tracking how it changes over time.

Further, next-generation sequencing (NGS) can be used for validating and detailed analysis of the complete SARS-CoV-2 genome. Highly automated NGS makes SARS-CoV-2 epidemiology research accessible and supports local, regional, and global surveillance efforts.

Many questions will be answered as the disease progresses. Meanwhile, we need to keep ourselves safe by tracking the mutations, even as we follow public health guidelines.

The writer is Managing Director, India and South Asia, Thermo Fisher Scientific. Views are personal

Published on December 27, 2021

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

COMMENTS
  1. Comments will be moderated by The Hindu editorial team.
  2. Comments that are abusive, personal, incendiary or irrelevant cannot be published.
  3. Please write complete sentences. Do not type comments in all capital letters, or in all lower case letters, or using abbreviated text. (example: u cannot substitute for you, d is not 'the', n is not 'and').
  4. We may remove hyperlinks within comments.
  5. Please use a genuine email ID and provide your name, to avoid rejection.

You May Also Like

Recommended for you